

Guillaume Cartron

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7496680/guillaume-cartron-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160
papers

6,819
citations

37
h-index

80
g-index

171
ext. papers

7,890
ext. citations

5.7
avg, IF

5.51
L-index

#	Paper	IF	Citations
160	Time for an individualized approach to first-line management of follicular lymphoma.. <i>Haematologica</i> , 2022 , 107, 7-18	6.6	2
159	Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3160-3169	1.9	
158	Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR. <i>Blood</i> , 2021 , 138, 641-641	2.2	1
157	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	0
156	The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High-Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 136-136	2.2	1
155	Coagulopathy Following Chimeric Antigen Receptor T Cell Therapy in R/R Adult B Cell Malignancies: A Single Center Experience. <i>Blood</i> , 2021 , 138, 4839-4839	2.2	
154	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). <i>Haematologica</i> , 2021 , 106, 2834-2844	6.6	1
153	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021 , 35, 2108-2113	10.7	4
152	A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. <i>Blood</i> , 2021 , 137, 2646-2656	2.2	10
151	G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death. <i>Blood Advances</i> , 2021 , 5, 2325-2338	7.8	4
150	Ruxolitinib for refractory large granular lymphocyte leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E368-E370	7.1	0
149	A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. <i>Blood</i> , 2021 , 137, 1019-1023	2.2	1
148	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. <i>Blood</i> , 2021 , 137, 877-887	2.2	21
147	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021 , 137, 2307-2320	2.2	16
146	Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021 , 35, 1597-1609	10.7	3
145	Follicular lymphoma dynamics. <i>Advances in Immunology</i> , 2021 , 150, 43-103	5.6	4
144	BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres. <i>British Journal of Haematology</i> , 2021 , 192, e94-e98	4.5	0

143	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 539-548	7.8	6
142	Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche. <i>Blood</i> , 2021 , 138, 57-70	2.2	7
141	Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. <i>Immunity</i> , 2021 , 54, 1788-1806.e7	32.3	8
140	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021 , 13,	6.6	2
139	Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 ,	2	1
138	Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.. <i>Frontiers in Immunology</i> , 2021 , 12, 755623	8.4	0
137	Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. <i>British Journal of Haematology</i> , 2020 , 190, e154-e156	4.5	36
136	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. <i>European Journal of Cancer</i> , 2020 , 136, 4-6	7.5	37
135	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. <i>Blood</i> , 2020 , 136, 20-21	2.2	0
134	DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets. <i>Blood</i> , 2020 , 136, 35-35	2.2	
133	Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. <i>Oncolmmunology</i> , 2020 , 10, 1853314	7.2	8
132	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , 2020 , 34, 1458-1461	10.7	11
131	The therapeutic effectiveness of Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. <i>Leukemia</i> , 2020 , 34, 1315-1328	10.7	5
130	DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets. <i>Cancers</i> , 2020 , 12,	6.6	1
129	Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. <i>Blood Advances</i> , 2020 , 4, 3217-3223	7.8	8
128	Dissecting the NK Cell Population in Hematological Cancers Confirms the Presence of Tumor Cells and Their Impact on NK Population Function. <i>Vaccines</i> , 2020 , 8,	5.3	5
127	Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma. <i>JAMA Network Open</i> , 2019 , 2, e192093	10.4	5
126	Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. <i>Theranostics</i> , 2019 , 9, 540-553	12.1	28

125	Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1495-1506	3.8	5
124	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019 , 133, 1964-1976	2.2	72
123	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019 , 6, e470-e479	14.6	14
122	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019 , 6, e429-e437	14.6	37
121	Immunological Approaches. <i>Technik Im Fokus</i> , 2019 , 307-324	0.3	
120	Infusion-related reactions to rituximab: frequency, mechanisms and predictors. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 383-389	5.1	25
119	Adverse reactions related to brentuximab vedotin use: A real-life retrospective study. <i>Therapie</i> , 2019 , 74, 343-346	3.8	5
118	Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. <i>Leukemia</i> , 2019 , 33, 776-780	10.7	9
117	Targeting the SUMO Pathway Primes All- Retinoic Acid-Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias. <i>Cancer Research</i> , 2018 , 78, 2601-2613	10.1	25
116	DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. <i>British Journal of Cancer</i> , 2018 , 118, 1062-1073	8.7	17
115	Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1705-1709	8.8	3
114	Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. <i>Haematologica</i> , 2018 , 103, e356-e359	6.6	5
113	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018 , 131, 174-181	2.2	78
112	Inherited or acquired modifiers of iron status may dramatically affect the phenotype in dehydrated hereditary stomatocytosis. <i>European Journal of Haematology</i> , 2018 , 101, 566-569	3.8	9
111	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018 , 132, 1486-1494	2.2	21
110	Mitochondrial Complex I activity signals antioxidant response through ERK5. <i>Scientific Reports</i> , 2018 , 8, 7420	4.9	15
109	Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors. <i>Theranostics</i> , 2018 , 8, 3856-3869	12.1	28
108	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 184-184	2.2	7

107	Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study. <i>Blood</i> , 2018 , 132, 999-999	2.2	7
106	A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B-Cell Lymphoma in Need of Systemic Therapy. <i>Blood</i> , 2018 , 132, 446-446	2.2	2
105	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018 , 132, 4196-4196	2.2	9
104	Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial. <i>Blood</i> , 2018 , 132, 4158-4158	2.2	5
103	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). <i>Blood</i> , 2018 , 132, 1859-1859	2.2	0
102	Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status. <i>Oncotarget</i> , 2018 , 9, 1114-1129	3.3	16
101	Occupational exposure to pesticides and prognosis of diffuse large B-cell lymphoma: A cohort study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1564-1564	2.2	
100	High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial. <i>Blood</i> , 2018 , 132, 1858-1858	2.2	
99	BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for Chemosensitive Relapses in Patients with Follicular Lymphoma: A Prospective Multicenter Phase II Study from Lymphoma Study Association (LYSA) Centers. <i>Blood</i> , 2018 , 132, 4612-4612	2.2	
98	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 5344 ² -5344		
97	Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. <i>Autoimmunity Reviews</i> , 2018 , 17, 115-124	13.6	35
96	NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. <i>Oncolmmunology</i> , 2018 , 7, e1409322	7.2	19
95	An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. <i>Oncotarget</i> , 2018 , 9, 19079-19099	3.3	7
94	PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. <i>Clinical Epigenetics</i> , 2018 , 10, 121	7.7	20
93	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 379, 934-947	59.2	168
92	miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. <i>Haematologica</i> , 2017 , 102, 746-754	6.6	16
91	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <i>Blood</i> , 2017 , 129, 2616-2623	2.2	57
90	Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. <i>Human Pathology</i> , 2017 , 64, 128-136	3.7	18

89	Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas. <i>Medical Physics</i> , 2017 , 44, 4608-4619	4.4	47
88	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. <i>Blood</i> , 2017 , 129, 2808-2810	2.2	39
87	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1250-1260	59.2	205
86	Obinutuzumab: what is there to learn from clinical trials?. <i>Blood</i> , 2017 , 130, 581-589	2.2	61
85	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 635-647	6.2	16
84	First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study. <i>Hematological Oncology</i> , 2017 , 35, 671-678	1.3	3
83	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. <i>Oncotarget</i> , 2016 , 7, 85573-85583	3.3	8
82	Gota et al. on their article "the pharmacokinetics of Reditux [®] biosimilar of rituximab". <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 1317-1318	3.5	2
81	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2016 , 101, 226-34	6.6	26
80	Scientific Significance of Clinically Insignificant FcRIIIa-V158F Polymorphism. <i>Clinical Cancer Research</i> , 2016 , 22, 787-9	12.9	4
79	Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1149-53	1.9	6
78	Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production. <i>EBioMedicine</i> , 2016 , 3, 43-53	8.8	33
77	Inherited and Acquired Modifiers of Iron Status May Dramatically Affect the Phenotypic Expression of Dehydrated Hereditary Stomatocytosis. <i>Blood</i> , 2016 , 128, 1281-1281	2.2	1
76	A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 4202-4202	2.2	4
75	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 4393-4393	2.2	16
74	CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity. <i>PLoS ONE</i> , 2016 , 11, e0150434	3.7	28
73	EZH2 in normal hematopoiesis and hematological malignancies. <i>Oncotarget</i> , 2016 , 7, 2284-96	3.3	56
72	Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 85-93	5.7	16

71	Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 2402-11	4.0	120
70	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. <i>Blood</i> , 2016 , 128, 1081-92	2.2	91
69	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016 , 127, 411-9	2.2	195
68	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. <i>Haematologica</i> , 2016 , 101, 976-84	6.6	49
67	Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 20	22.4	15
66	DNA repair in diffuse large B-cell lymphoma: a molecular portrait. <i>British Journal of Haematology</i> , 2015 , 169, 296-9	4.5	10
65	Obinutuzumab in hematologic malignancies: lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015 , 41, 784-92	14.4	37
64	New anti-CD20 monoclonal antibodies: which is the best?. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1-2	1.9	20
63	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. <i>Blood</i> , 2015 , 126, 2646-9	2.2	49
62	Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers. <i>EBioMedicine</i> , 2015 , 2, 1364-76	8.8	18
61	First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study. <i>Blood</i> , 2015 , 126, 4170-4170	2.2	1
60	Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 829-829	2.2	5
59	The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. <i>Oncotarget</i> , 2015 , 6, 19228-45	3.3	21
58	Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated-Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial GoELans-075. <i>Blood</i> , 2015 , 126, 3928-3928	2.2	
57	Metabolic Tumor Volume Influences Response to Brentuximab-Vedotin in Relapsed Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 588-588	2.2	
56	Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant. <i>Journal of Medical Virology</i> , 2014 , 86, 851-6	19.7	15
55	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014 , 93, 233-42	3	17
54	Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. <i>Blood</i> , 2014 , 124, 2196-202	2.2	125

53	Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis. <i>Mediators of Inflammation</i> , 2014 , 2014, 342524	4.3	69
52	Obinutuzumab: a new class of anti-CD20 monoclonal antibody. <i>Current Opinion in Oncology</i> , 2014 , 26, 484-91	4.2	31
51	Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients. <i>Journal of Clinical Immunology</i> , 2013 , 33, 22-9	5.7	11
50	Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2920-6	2.2	124
49	High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. <i>British Journal of Haematology</i> , 2013 , 162, 240-9	4.5	8
48	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. <i>Haematologica</i> , 2013 , 98, 1107-14	6.6	62
47	Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 104-10	2.2	115
46	Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2912-9	2.2	159
45	Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). <i>Blood</i> , 2013 , 122, 1137-43	2.2	95
44	Monoclonal Antibodies for Lymphoma 2013 , 345-361		1
43	Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 597-605	3.8	19
42	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i> , 2012 , 119, 3698-704	2.2	118
41	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. <i>Blood</i> , 2012 , 119, 5126-32	2.2	159
40	Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. <i>Blood</i> , 2012 , 120, 2650-7	2.2	47
39	Clinical radioimmunotherapy--the role of radiobiology. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 720-34	19.4	145
38	Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3627-33	4.3	16
37	Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. <i>Haematologica</i> , 2011 , 96, 1128-35	6.6	84
36	Interindividual variability of response to rituximab: from biological origins to individualized therapies. <i>Clinical Cancer Research</i> , 2011 , 17, 19-30	12.9	69

35	Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000). <i>Blood</i> , 2011 , 118, 270-270	2.2	7
34	Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011 , 118, 2862-2862	2.2	6
33	Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),. <i>Blood</i> , 2011 , 118, 3704-3704	2.2	3
32	Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia. <i>Acta Dermato-Venereologica</i> , 2010 , 90, 99-100	2.2	6
31	High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma. <i>Experimental and Therapeutic Medicine</i> , 2010 , 1, 933-938	2.1	11
30	Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 975-82 ⁴		37
29	Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients □ First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL. <i>Blood</i> , 2010 , 116, 2878-2878	2.2	6
28	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 561-73	3.8	17
27	FCGR3A polymorphism story: a new piece of the puzzle. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1401-2	1.9	6
26	Hybrid gadolinium oxide nanoparticles combining imaging and therapy. <i>Journal of Materials Chemistry</i> , 2009 , 19, 2328		65
25	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. <i>Blood</i> , 2009 , 113, 3765-72	2.2	102
24	Phase I Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009 , 114, 1704-1704	2.2	16
23	Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 884-884	2.2	30
22	Evidence for linkage disequilibrium between Fcγ3a R13A-V158F and Fcγ3a R13A-H131R polymorphisms in white patients, and for an Fcγ3a R13A-restricted influence on the response to therapeutic antibodies. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5489-91; author reply 5491-2	2.2	54
21	Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2725-31	2.2	69
20	A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease. <i>Blood</i> , 2008 , 112, 234-234	2.2	13
19	Late Relapse of Localized High-Grade Non-Hodgkin's Lymphoma: Clinical and Biological Features. <i>Blood</i> , 2008 , 112, 2603-2603	2.2	2
18	In Follicular Lymphoma (FL), B-Lymphocytes (III) Are Present and Expandable from Peripheral Blood and Rare in Tumour Lymph Nodes, Mostly in Peri-Follicular Areas.. <i>Blood</i> , 2008 , 112, 1773-1773	2.2	

17	Pharmacokinetics of rituximab and its clinical use: thought for the best use?. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 62, 43-52	7	97
16	Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 62, 34-42	7	64
15	Biotherapies: are they just like any other drugs?. <i>Therapie</i> , 2007 , 62, 229-39	3.8	1
14	Maintenance therapy for low-grade lymphomas: has the time come?. <i>Current Opinion in Oncology</i> , 2007 , 19, 425-32	4.2	4
13	CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. <i>FASEB Journal</i> , 2006 , 20, 1913-5	0.9	47
12	Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies. <i>Blood</i> , 2005 , 106, 1503-4; author reply 1504-5	2.2	9
11	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 273-86	7.4	16
10	Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. <i>Cancer Research</i> , 2004 , 64, 4664-9	10.1	356
9	From the bench to the bedside: ways to improve rituximab efficacy. <i>Blood</i> , 2004 , 104, 2635-42	2.2	443
8	Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801A Polymorphism in De Novo Acute Myeloid Leukemia.. <i>Blood</i> , 2004 , 104, 66-66	2.2	4
7	Efficacy and Safety of Alemtuzumab in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia after Autologous Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 2509-2509	2.2	1
6	Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. <i>Experimental Hematology</i> , 2003 , 31, 89-97	3.1	7
5	Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy: a comparison with steady-state bone marrow and peripheral blood. <i>Experimental Hematology</i> , 2002 , 30, 74-81	3.1	15
4	Quantitative and qualitative analysis of the human primitive progenitor cell compartment after autologous stem cell transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002 , 11, 359-68		7
3	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. <i>Blood</i> , 2002 , 99, 754-8	2.2	1607
2	Prognostic factors for lymphomas 2001 , 32-54		
1	Nonclassical monocytes are prone to migrate into tumor in diffuse large B-cell lymphoma		1